|

Gemcitabine (1000 mg/m2) Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since July 2026

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Inhibrx Biosciences, Inc1
  • Hospital Universitario Dr. Jose E. Gonzalez1

Indications

  • Cancer2
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma1
  • Resectable Non-Small-Cell Lung Cancer1
  • Renal Cell Carcinoma1
  • Urothelial Carcinoma1

Other1 trial

Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Phase 2

Duarte, California1 trial

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

City of Hope

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.